{"id":"oral-cab","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CAB (cabotegravir) is an integrase strand transfer inhibitor (INSTI) that works by blocking HIV integrase, the enzyme responsible for inserting viral DNA into the host genome. The oral formulation allows for daily dosing as an alternative to long-acting injectable formulations. It is often used in combination antiretroviral therapy to suppress HIV replication.","oneSentence":"Oral CAB is a capsid assembly modulator that inhibits HIV capsid formation, preventing viral replication by disrupting the structural integrity of newly formed HIV particles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:52.368Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naive and treatment-experienced adults (in combination with other antiretroviral agents)"}]},"trialDetails":[{"nctId":"NCT07497893","phase":"NA","title":"FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)","status":"NOT_YET_RECRUITING","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2026-12-01","conditions":"Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB), Gastrointestinal Hemorrhage (Clinically Important, Upper)","enrollment":1000},{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT02720094","phase":"PHASE2, PHASE3","title":"Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-19","conditions":"HIV Infections","enrollment":4570},{"nctId":"NCT07479056","phase":"NA","title":"Randomized Active-Controlled Trial Evaluating Fexuprazan (Fexuclue Tab) for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention","status":"RECRUITING","sponsor":"SUK MIN SEO","startDate":"2024-10-24","conditions":"Diseases of the Circulatory System, Angina Pectoris, Unspecified","enrollment":400},{"nctId":"NCT07473778","phase":"","title":"Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention","status":"NOT_YET_RECRUITING","sponsor":"Gilead Sciences","startDate":"2026-03","conditions":"HIV Infections","enrollment":3000},{"nctId":"NCT07463235","phase":"PHASE3","title":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-04","conditions":"Prolactinoma, Prolactin Excess","enrollment":70},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT06694805","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-12-02","conditions":"HIV Infections","enrollment":332},{"nctId":"NCT07314333","phase":"PHASE1","title":"A Trial to Assess How Centanafadine Interacts With Stimulants in the Body","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-02-05","conditions":"ADHD","enrollment":42},{"nctId":"NCT05726019","phase":"PHASE2","title":"Colchicine in Patients Undergoing Coronary Artery Bypass Grafting After Acute Coronary Syndrome","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2022-02-05","conditions":"Coronary Artery Disease, Acute Coronary Syndrome, Coronary Artery Bypass","enrollment":100},{"nctId":"NCT04979728","phase":"","title":"HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-05-27","conditions":"HIV Treatment, HIV Prevention","enrollment":150},{"nctId":"NCT07437768","phase":"NA","title":"Vonoprazan Test for PPI Refractory GERD","status":"ENROLLING_BY_INVITATION","sponsor":"Fu Jen Catholic University Hospital","startDate":"2025-12-24","conditions":"Refractory GERD, NERD, PCAB","enrollment":100},{"nctId":"NCT07013591","phase":"PHASE2","title":"Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-03-31","conditions":"Coronary Artery Bypass Graft","enrollment":90},{"nctId":"NCT07348133","phase":"PHASE1","title":"Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2025-12-11","conditions":"Healthy","enrollment":18},{"nctId":"NCT06104306","phase":"PHASE4","title":"Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2023-12-13","conditions":"HIV-1-infection","enrollment":33},{"nctId":"NCT07397221","phase":"NA","title":"Oropharyngeal Humidification After Extubation on Thirst","status":"NOT_YET_RECRUITING","sponsor":"Muş Alparslan University","startDate":"2026-02-01","conditions":"Coronary Artery Bypass","enrollment":42},{"nctId":"NCT05514509","phase":"PHASE4","title":"A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-10-28","conditions":"HIV Infections","enrollment":370},{"nctId":"NCT07390409","phase":"","title":"ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.","status":"NOT_YET_RECRUITING","sponsor":"Desmond Tutu HIV Foundation","startDate":"2026-01-29","conditions":"HIV","enrollment":3700},{"nctId":"NCT06411223","phase":"PHASE2","title":"Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2024-08-01","conditions":"Hiv","enrollment":50},{"nctId":"NCT03497676","phase":"PHASE1, PHASE2","title":"More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-03","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT03410420","phase":"PHASE1","title":"Detection of Hypoxia in Human Thoracic Aorta Using Pimonidazole Hydrochloride","status":"COMPLETED","sponsor":"Thomas Gleason","startDate":"2018-09-01","conditions":"Aortic Aneurysm, Thoracic","enrollment":9},{"nctId":"NCT07326904","phase":"PHASE3","title":"Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2024-09-23","conditions":"Gastro Oesophageal Reflux Disease","enrollment":145},{"nctId":"NCT07307716","phase":"NA","title":"Clear Aligner Cleaning: Brushing, Chlorhexidine, and BlueM Effects on Oral Microbial Ecology and Periodontal Indices","status":"NOT_YET_RECRUITING","sponsor":"Riyadh Elm University","startDate":"2026-02","conditions":"Gingivitis, Dental Plaque","enrollment":21},{"nctId":"NCT07195149","phase":"PHASE3","title":"Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)","status":"RECRUITING","sponsor":"Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.","startDate":"2025-11-25","conditions":"Chronic Coronary Syndrome, Stable Coronary Artery Disease CAD","enrollment":1703},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT07267260","phase":"PHASE2","title":"Evaluating the Efficacy of Vonoprazan in Preventing Post-Endoscopic Variceal Band Ligation Ulcers: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"King Edward Medical University","startDate":"2025-12-16","conditions":"Cirrhoses, Liver","enrollment":154},{"nctId":"NCT07268820","phase":"PHASE4","title":"Heartburn, Gastroesophageal Reflux Disease","status":"RECRUITING","sponsor":"Incheon St.Mary's Hospital","startDate":"2025-07-07","conditions":"GERD","enrollment":160},{"nctId":"NCT05997693","phase":"PHASE3","title":"One-Month DAPT in CABG Patients","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-08-15","conditions":"Chronic Coronary Disease","enrollment":700},{"nctId":"NCT07275606","phase":"PHASE1, PHASE2","title":"A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1","status":"NOT_YET_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2026-03-17","conditions":"HIV Infections","enrollment":66},{"nctId":"NCT05010460","phase":"PHASE2","title":"Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting","status":"TERMINATED","sponsor":"Peking Union Medical College Hospital","startDate":"2021-09-30","conditions":"Coronary Artery Bypass","enrollment":98},{"nctId":"NCT07242443","phase":"PHASE4","title":"Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori）","status":"NOT_YET_RECRUITING","sponsor":"First People's Hospital of Hangzhou","startDate":"2025-11-20","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":240},{"nctId":"NCT03164564","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-11-07","conditions":"HIV Infections","enrollment":3224},{"nctId":"NCT06730945","phase":"PHASE4","title":"Effect of Oral Isosorbide Mononitrate Plus Amlodipine Antispasm Therapy on Outcomes of Radial Artery Grafts After CABG","status":"WITHDRAWN","sponsor":"Ruijin Hospital","startDate":"2025-06","conditions":"Coronary Artery Bypass Graft Surgery (CABG), Radial Artery Grafts, Graft Failure","enrollment":""},{"nctId":"NCT03635788","phase":"PHASE3","title":"The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-28","conditions":"HIV Infections","enrollment":456},{"nctId":"NCT04131556","phase":"PHASE1","title":"A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants","status":"TERMINATED","sponsor":"Shire","startDate":"2019-10-25","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT03299049","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2017-10-27","conditions":"HIV Infections","enrollment":1049},{"nctId":"NCT06340581","phase":"PHASE1","title":"A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2024-10-17","conditions":"Healthy","enrollment":""},{"nctId":"NCT06290102","phase":"PHASE1","title":"Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-05-16","conditions":"Asthma","enrollment":30},{"nctId":"NCT07117331","phase":"NA","title":"Technology-Enhanced Continuous Nursing System (TECNS) for Post-CABG Recovery","status":"COMPLETED","sponsor":"The First Hospital of Hebei Medical University","startDate":"2018-01-01","conditions":"Coronary Artery Disease","enrollment":358},{"nctId":"NCT06979388","phase":"PHASE1","title":"A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-05-20","conditions":"Healthy Participants","enrollment":14},{"nctId":"NCT06336434","phase":"PHASE1, PHASE2","title":"CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-01","conditions":"HIV-1-infection, Pregnancy, Postpartum","enrollment":""},{"nctId":"NCT06397690","phase":"NA","title":"Supporting Oral and Long-acting PrEP Decision Making Among Pregnant Women in Lilongwe, Malawi","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-02-10","conditions":"HIV Prevention","enrollment":75},{"nctId":"NCT04493684","phase":"PHASE1","title":"GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-07-31","conditions":"HIV Infections","enrollment":91},{"nctId":"NCT07062432","phase":"NA","title":"Continuous Comprehensive Nursing for Post-CABG Recovery","status":"COMPLETED","sponsor":"The First Hospital of Hebei Medical University","startDate":"2020-02-01","conditions":"Coronary Heart Disease (CHD)","enrollment":120},{"nctId":"NCT07031128","phase":"PHASE4","title":"Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS)","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2024-06-11","conditions":"CABG","enrollment":250},{"nctId":"NCT06955520","phase":"NA","title":"Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM","status":"RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2025-04-30","conditions":"GERD","enrollment":300},{"nctId":"NCT05601128","phase":"PHASE3","title":"A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA","status":"COMPLETED","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2023-01-01","conditions":"HIV-1-infection, HIV Infections, HIV I Infection","enrollment":12},{"nctId":"NCT06995586","phase":"NA","title":"Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","status":"NOT_YET_RECRUITING","sponsor":"Nicosia General Hospital","startDate":"2025-09-01","conditions":"Cardio-pulmonary Bypass, Cardiovascular Diseases, Omega-3 Polyunsaturated Fatty Acids","enrollment":108},{"nctId":"NCT05660980","phase":"PHASE1, PHASE2","title":"Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-24","conditions":"HIV-1-infection","enrollment":90},{"nctId":"NCT03739996","phase":"PHASE2","title":"Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-31","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT04844424","phase":"PHASE1","title":"A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-14","conditions":"Healthy","enrollment":115},{"nctId":"NCT04692077","phase":"PHASE2","title":"Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-02-19","conditions":"HIV Infections","enrollment":9},{"nctId":"NCT02733341","phase":"PHASE4","title":"The Effect of IV Cangrelor and Oral Ticagrelor Study","status":"COMPLETED","sponsor":"The Royal Wolverhampton Hospitals NHS Trust","startDate":"2016-07-21","conditions":"Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO)","enrollment":100},{"nctId":"NCT04553042","phase":"PHASE1","title":"A Study of Seltorexant in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-14","conditions":"Healthy","enrollment":69},{"nctId":"NCT02919579","phase":"PHASE1","title":"A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-10-07","conditions":"Depressive Disorder, Major","enrollment":27},{"nctId":"NCT05392530","phase":"PHASE1","title":"A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult Participants","status":"COMPLETED","sponsor":"Actelion","startDate":"2022-05-25","conditions":"Healthy","enrollment":23},{"nctId":"NCT04388501","phase":"PHASE1","title":"A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2021-06-07","conditions":"Healthy","enrollment":23},{"nctId":"NCT05236231","phase":"PHASE1","title":"A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants","status":"COMPLETED","sponsor":"Actelion","startDate":"2022-02-04","conditions":"Healthy","enrollment":40},{"nctId":"NCT04448964","phase":"PHASE1","title":"A Study of JNJ-70033093 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-26","conditions":"Healthy","enrollment":24},{"nctId":"NCT06898112","phase":"","title":"Mixed-methods Protocol for the WiSSPr Study","status":"COMPLETED","sponsor":"Centre for Infectious Disease Research in Zambia","startDate":"2023-07-18","conditions":"PrEP Uptake","enrollment":299},{"nctId":"NCT06158126","phase":"PHASE4","title":"UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-04-17","conditions":"Pre-exposure Prophylaxis, HIV Prevention, Pregnancy Related","enrollment":621},{"nctId":"NCT06646562","phase":"PHASE4","title":"Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.","status":"RECRUITING","sponsor":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","startDate":"2025-03-03","conditions":"HIV-1 Infected Adults with Controlled Viremia","enrollment":120},{"nctId":"NCT05393882","phase":"","title":"Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency","status":"WITHDRAWN","sponsor":"Chinese University of Hong Kong","startDate":"2025-09","conditions":"Coronary Artery Disease, Bypass Graft Stenosis, Dyslipidemias","enrollment":""},{"nctId":"NCT06656676","phase":"NA","title":"WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-01-29","conditions":"HIV Prevention","enrollment":75},{"nctId":"NCT05578846","phase":"PHASE1","title":"Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-10-13","conditions":"Healthy Adult Participants","enrollment":42},{"nctId":"NCT05755204","phase":"","title":"A Pharmacist-run PrEP Program for Women","status":"TERMINATED","sponsor":"Orlando Immunology Center","startDate":"2023-06-21","conditions":"HIV Prevention","enrollment":2},{"nctId":"NCT03805048","phase":"NA","title":"PeRcutaneous cOronary Intervention of Native Coronary arTery Versus Venous Bypass Graft in Patients With Prior CABG","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2019-01-22","conditions":"Coronary Artery Disease","enrollment":221},{"nctId":"NCT03010059","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-02-06","conditions":"Healthy","enrollment":48},{"nctId":"NCT02405858","phase":"PHASE4","title":"A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2015-04-10","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":51},{"nctId":"NCT02984852","phase":"PHASE1","title":"Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2016-12","conditions":"Healthy","enrollment":30},{"nctId":"NCT04090086","phase":"PHASE1","title":"A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-16","conditions":"Healthy","enrollment":16},{"nctId":"NCT05155007","phase":"PHASE1","title":"A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-12-10","conditions":"Healthy","enrollment":18},{"nctId":"NCT06788951","phase":"NA","title":"The Effect of Oral Carbohydrate Inhalation Given to Patients Before Coronary Artery Bypass Graft Operation on Recovery","status":"COMPLETED","sponsor":"Yasemin Bozkurt","startDate":"2024-03-08","conditions":"Surgery","enrollment":120},{"nctId":"NCT04973254","phase":"NA","title":"Improving Treatment and Retention Adherence in Nontraditional Settings","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2022-02-23","conditions":"HIV Infections","enrollment":25},{"nctId":"NCT06704204","phase":"","title":"Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community","status":"NOT_YET_RECRUITING","sponsor":"The Miriam Hospital","startDate":"2025-02","conditions":"HIV","enrollment":20},{"nctId":"NCT04310995","phase":"PHASE4","title":"Different Anti-Spastic Therapy Strategies After CABG Using Radial Artery Grafts","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2020-06-02","conditions":"Coronary Artery Bypass Graft, Radial Artery Grafts, Antispastic Therapy","enrollment":150},{"nctId":"NCT06114719","phase":"PHASE3","title":"Silymarin for the Prevention of Atrial Fibrillation After Cardiac Surgery","status":"COMPLETED","sponsor":"University of Novi Sad","startDate":"2023-01-01","conditions":"Atrial Fibrillation New Onset","enrollment":160},{"nctId":"NCT04824131","phase":"PHASE2","title":"Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-11-04","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT06157918","phase":"PHASE1","title":"Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants","status":"COMPLETED","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2023-12-20","conditions":"Healthy Participants","enrollment":19},{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT06211179","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-01-10","conditions":"Healthy Volunteers","enrollment":34},{"nctId":"NCT06090487","phase":"NA","title":"Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function Performance","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-02-01","conditions":"Heart Failure","enrollment":30},{"nctId":"NCT06565013","phase":"","title":"Chemsex Health Evaluation With Extended Release System for HIV Treatment","status":"NOT_YET_RECRUITING","sponsor":"Clinique Médicale L'Actuel","startDate":"2024-08","conditions":"HIV","enrollment":50},{"nctId":"NCT06072443","phase":"","title":"AURORA Study-A Transformative Approach to Support PrEP Medication Persistence","status":"RECRUITING","sponsor":"WV Health Right, Inc.","startDate":"2023-11-30","conditions":"HIV Infections","enrollment":105},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT03639311","phase":"PHASE2","title":"Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-09-24","conditions":"HIV Infections","enrollment":97},{"nctId":"NCT04542070","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-11-09","conditions":"HIV Infections","enrollment":687},{"nctId":"NCT06397508","phase":"PHASE1","title":"Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants","status":"COMPLETED","sponsor":"Agomab Spain S.L.","startDate":"2024-04-02","conditions":"Healthy Volunteers","enrollment":25},{"nctId":"NCT06405464","phase":"","title":"Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2022-03-01","conditions":"HIV Infections","enrollment":600},{"nctId":"NCT05154747","phase":"PHASE3","title":"Long-Acting Treatment in Adolescents (LATA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2023-06-22","conditions":"Hiv, HIV Infections, HIV-1-infection","enrollment":476},{"nctId":"NCT06250504","phase":"PHASE3","title":"Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT","status":"RECRUITING","sponsor":"Africa Health Research Institute","startDate":"2024-02-27","conditions":"HIV Infections","enrollment":2000},{"nctId":"NCT04399551","phase":"PHASE3","title":"A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-09-28","conditions":"HIV Infections","enrollment":437},{"nctId":"NCT06332638","phase":"PHASE1","title":"PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects","status":"ENROLLING_BY_INVITATION","sponsor":"HK inno.N Corporation","startDate":"2024-03-19","conditions":"Healthy","enrollment":36},{"nctId":"NCT04857892","phase":"PHASE1","title":"A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-04-21","conditions":"HIV Infections","enrollment":41},{"nctId":"NCT06273943","phase":"PHASE3","title":"Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-01","conditions":"Prevention","enrollment":322},{"nctId":"NCT01896505","phase":"PHASE1","title":"A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2013-07-30","conditions":"Sarcoma","enrollment":54},{"nctId":"NCT05723510","phase":"PHASE1","title":"PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2023-03-06","conditions":"Healthy","enrollment":87},{"nctId":"NCT06164834","phase":"PHASE1","title":"Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2023-12-05","conditions":"Healthy","enrollment":48},{"nctId":"NCT04484337","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-07-31","conditions":"HIV Infections","enrollment":138},{"nctId":"NCT04502849","phase":"","title":"Apoptosis Proteins and Endothelial Dysfunction in Patients With Atherosclerosis of Peripheral Arteries","status":"COMPLETED","sponsor":"Ryazan State Medical University","startDate":"2020-01-01","conditions":"Atherosclerosis, Endothelial Dysfunction","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cabotegravir","GSK1265744"],"phase":"phase_3","status":"active","brandName":"Oral CAB","genericName":"Oral CAB","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral CAB, also known as the \"Protect Study,\" is a pilot study that investigated the use of Periostat, a doxycycline derivative, in protecting the heart during coronary artery bypass grafting. The study was conducted at the University of Alberta and involved conditions such as coronary artery bypass grafting, cardiopulmonary bypass, and reperfusion injury.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}